Tissue engineered heart valve to enter human trials:
This article was originally published in Clinica
US company CryoLife plans to begin human trials of a new tissue-engineered heart valve which combines living human cells with a porcine heart valves to mimic more closely a natural human valve. The Atlanta, Georgia-based company plans to submit an investigational device exemption to the US FDA in the fourth quarter of 1999 for its SynerGraft technology. Last month, the company announced that SynerGraft porcine valves implanted in sheep were functional and showed no signs of calcification after 160 days.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.